Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Connor, J.R.a; * | Milward, E.A.b | Moalem, S.c | Sampietro, M.d | Boyer, P.a; e | Percy, M.E.c | Vergani, C.d | Scott, R.J.g | Chorney, M.f
Affiliations: [a] Department of Neuroscience & Anatomy, Penn State University College of Medicine, M.S. Hershey Medical Center, Hershey PA, USA | [b] Department of Neurology, Johns Hopkins University, Baltimore MD, USA | [c] Department of Physiology, University of Toronto, Toronto ON, Canada | [d] Department of Internal Medicine, University of Milan & IRCCS Ospedale Maggiore, Milan, Italy | [e] Department of Pathology, Penn State University College of Medicine, M.S. Hershey Medical Center, Hershey PA, USA | [f] Department of Microbiology & Immunology, Penn State University College of Medicine, M.S. Hershey Medical Center, Hershey PA, USA | [g] Discipline of Medical Genetics, Faculty of Medicine and Health Sciences, University of Newcastle, Australia
Correspondence: [*] Corresponding author.
Note: [] Communicated by Paolo Zatta.
Abstract: Excess iron accumulation in the brain is a consistent observation in Alzheimer's Disease. Iron affects amyloid precursor protein (AβPP) processing and promotes deposition of Aβ. Iron is also among the most potent biological toxins because of its ability to react with oxygen to form reactive oxygen species. Consequently, elucidation of the mechanisms associated with maintaining brain iron homeostasis is fundamentally important to understanding the underlying pathogenesis in AD. The iron overload disorder, Hemochromatosis, is the most common genetic disorder (1:200) so a significant percentage of AD patients can be expected to carry this mutation. Heterozygotes for this mutation also have an increased, but sub-clinical iron burden. Given the high percentage of the population who are at significant risk for iron overload, we propose that the hemochromatosis mutation be considered as a confounding factor when evaluating the contribution of genetic associations with AD and treatment strategies and efficacy. Two recent papers and new evidence presented here that the protein associated with hemochromatosis is expressed on blood vessels, choroid plexus and the ependymal cells in the brain are offered as support for this proposal.
DOI: 10.3233/JAD-2001-3506
Journal: Journal of Alzheimer's Disease, vol. 3, no. 5, pp. 471-477, 2001
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl